Trials / Completed
CompletedNCT01576367
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 1 Year – 4 Years
- Healthy volunteers
- Not accepted
Summary
This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study
Conditions
- Cryopyrin-associated Periodic Syndromes
- Familial Cold Autoinflammatory Syndrome
- Muckle-Wells Syndrome
- Neonatal Onset Multisystem Inflammatory Disease
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACZ885 |
Timeline
- Start date
- 2012-01-16
- Primary completion
- 2015-10-13
- Completion
- 2015-10-13
- First posted
- 2012-04-12
- Last updated
- 2018-09-11
- Results posted
- 2016-08-03
Locations
12 sites across 7 countries: Belgium, Canada, France, Germany, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01576367. Inclusion in this directory is not an endorsement.